Compare Autozone Inc (AZO) vs IDEXX Laboratories, Inc. (IDXX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Autozone Inc vs IDEXX Laboratories, Inc. — how do they compare? Autozone Inc trades at $3,042 (market cap $49.67B), while IDEXX Laboratories, Inc. trades at $571 (market cap $46.22B). The key difference: Autozone Inc and IDEXX Laboratories, Inc. are close in size by market cap, and IDEXX Laboratories, Inc. is trading nearer its 52-week high, Autozone Inc nearer its low. Which is the better fit depends on your goals.
| AZO | IDXX | |
|---|---|---|
Market Cap | $49.67B | $46.22B |
Sector | Consumer Cyclical | Health |
52-Week High | $4.35K | $766.68 |
52-Week Low | $2.92K | $526.44 |
Enterprise Value | $62.05B | $47.12B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AutoZone (AZO) trades at $3,045.87, down 0.72% with bearish technical signals despite strong analyst support. The company maintains solid fundamentals with $18.94B revenue and 12.4% net margin, though recent Q3 2025 EPS missed expectations while Q4 2025 and Q1 2026 beat. Operating cash flow remains robust at $3.12B, supporting ongoing expansion initiatives. Recent organizational changes and international growth strategies highlight management's focus on long-term value creation.
AZO presents a compelling value opportunity with 72.7% analyst buy ratings and $3,730 consensus price target representing 22% upside. Key risks include margin compression trends and competitive pressures in auto parts retail. The stock's current technical weakness contrasts with strong institutional conviction, creating potential for recovery if earnings momentum improves.
IDEXX Laboratories (IDXX) trades at $570.58, down 4.23% over 24 hours, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates, with Q2 2026 EPS of $4.27 surpassing the $3.94 expectation. Revenue growth remains robust, supported by a 74.21% ROE and expanding diagnostic offerings. Recent news highlights product expansion, including a dual-species cardiac test, reinforcing its market leadership in veterinary diagnostics.
The outlook is positive, driven by durable competitive advantages and international growth potential. However, elevated valuation multiples and competitive pressures pose risks. Analyst consensus is bullish with a $683.33 price target, suggesting significant upside from current levels, though investors should monitor execution on guidance and macroeconomic headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Autozone Inc
AutoZone is the premier seller of aftermarket automotive parts, tools, and accessories to do-it-yourself customers in the United States. The company derives an increasing proportion of its sales from domestic commercial customers, although its presence in its home market is still dominated by its do-it-yourself operation, which accounts for nearly 75% of sales in country. AutoZone also has a growing presence in Mexico and Brazil. AutoZone had 6,767 stores in the U.S. (6,051), Mexico (664), and Brazil (52) as of the end of fiscal 2021.
Read more on AZO →About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →
